Navigation Links
AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Date:5/30/2008

ry, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information visit http://www.astrazeneca-us.com.

References

(1) Data on File. AstraZeneca Pharmaceuticals LP. 263698.

(2) J. J.Y. Sung et al. Intravenous esomeprazole for prevention of peptic

ulcer re-bleeding: rationale/design of the Peptic Ulcer Bleed study.

Aliment Pharmacol Ther 2008; 27:666-677.

(3) NEXIUM I.V. Prescribing Information. Indications and usage section.

(4) Lassen et al. Complicated and uncomplicated peptic ulcers in a Danish

county 1993-2002: a population-based cohort study. Am J Gastroenterol

2006;101(5):945-53.

(5) Kang JY et al. Recent trends in hospital admissions and mortality

rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther

2006;24(1):65-79.

(6) Soplepmann et al. Peptic ulcer haemorrhage in Tartu County, Estonia:

epidemiology and mortality risk factors. Scand J Gastroenterol

1997;32(12):1195-200.

(7) Thomsen et al. Diabetes and 30-day mortality from peptic ulcer

bleeding and perforation: a Danish population-based cohort study.

Diabetes Care 2006;29(4):805-10.

(8) van Leerdam ME et al Acute upper GI bleeding: Did anything change?

Time trend analysis of incidence and outcome of acute upper GI

bleeding between 1993/1994 and 2000. American Journal of

Gastroenterology 2003;98(7):1494-1499. Table 5.

(9) Mose et al. Thirty-day mortality after peptic ulcer bleeding in

hospitalized patients receiving low-dose aspirin at time of

admission. Am J Ge
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
2. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
3. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
4. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
8. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
9. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
10. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... schizophrenia twice as likely to have children with the ... News) -- Parents of children with autism have double ... condition than parents of children without autism, according to ... the information may provide a way for experts to ...
... its Kind in the U.S. to Address Epidemic Drug & Alcohol Use, by Suburban Teens; Integrates Academics, Intervention, ... Hope; Teens to Share Personal Stories, MENDHAM, N.J., May 5 , WHAT: ... next ... nation,s only fully-licensed coeducational special ed ...
... Club Members Share Life-Changing Experiences, SAN RAMON, ... largest,national fitness club chain, today launched an innovative ... overcome personal challenges,through fitness. The "12 Million Lives" ... a life-changing journey by using the power of ...
... announced plans to,align their Ophthalmic Strategic Business Unit (Lumenis ... the highest standards of,quality and reliability., Lumenis, Ophthalmic ... who will lead the unit for the present time ... for Business Development, and,will replace Mr. Jake Vander Zanden, ...
... enrolling in the state childrens health insurance program (SCHIP) ... would further prolong these childrens need to address asthma ... which happens when patients switch to SCHIP when they ... waiting periods to qualify for SCHIP. Waiting periods ...
... LABAs ARE SAFE AND EFFECTIVE FOR COPD , ... (LABA) to increased risk for adverse events or respiratory-related ... obstructive pulmonary disease (COPD); however, a recent article shows ... metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the ...
Cached Medicine News:Health News:Autistic Kids More Likely to Have Parents With Mental Illness 2Health News:Daytop - NJ to Dedicate New Preparatory School This Week 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 3Health News:Lumenis Announces changes in Lumenis Vision Strategic Business Unit 2Health News:New SCHIP enrollees have unmet health care needs 2Health News:News briefs: May issue of the journal Chest 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: